Additional analyses of the two trials presented at 2023 ESC Congress
But findings apply only to middle-aged or older men with confirmed hypogonadism
Findings hold implications for screening and potential nonsurgical therapy
Potential benefits include clinical guidance, TAVR outcome prediction, device testing
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Network proximity and EHR analyses identify diabetes drug as a top candidate for risk reduction
Sophisticated in vivo modeling can enhance device development and therapy testing
DT-MRI and RNA-FISH show increase in CITED4 promotes healthy architecture of myocardium
Prospective SPIRIT-HCM trial demonstrates broad gains over 12-month follow-up
First report of major endpoint reduction in patients with biopsy-proven NASH
TMAO pathway impacts infarct size and functional impairment in preclinical stroke models
Advertisement
Advertisement